NCT02689453 2022-04-29
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
National Institutes of Health Clinical Center (CC)
Kyowa Kirin Co., Ltd.